Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-16 6:49 pm Sale |
2025-04-14 | 13G | Third Harmonic Bio, Inc. THRD |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-2,372,933 (Position Closed) |
Filing History |
| 2025-04-09 09:00 am Unchanged |
2025-04-09 | 13D | ESSA Pharma Inc. EPIX |
BIOTECHNOLOGY VALUE FUND L P | 8,748,629 19.700% |
0 (Unchanged) |
Filing History |
| 2025-02-14 4:28 pm Purchase |
2024-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN |
BIOTECHNOLOGY VALUE FUND L P | 3,084,324 9.970% |
307,079 (+11.06%) |
Filing History |
| 2025-02-14 4:26 pm Purchase |
2024-12-31 | 13G | Verastem, Inc. VSTM |
BIOTECHNOLOGY VALUE FUND L P | 4,706,551 9.990% |
427,030 (+9.98%) |
Filing History |
| 2025-02-14 4:24 pm Sale |
2024-12-31 | 13G | Tyra Biosciences, Inc. TYRA |
BIOTECHNOLOGY VALUE FUND L P | 3,944,194 7.800% |
-717,000 (-15.38%) |
Filing History |
| 2025-02-14 4:22 pm Sale |
2024-12-31 | 13G | Ikena Oncology, Inc. IKNA |
BIOTECHNOLOGY VALUE FUND L P | 4,006,564 8.300% |
-762,600 (-15.99%) |
Filing History |
| 2025-02-14 4:20 pm Sale |
2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
BIOTECHNOLOGY VALUE FUND L P | 4,834,297 9.990% |
-2,548,345 (-34.52%) |
Filing History |
| 2025-02-14 4:11 pm Purchase |
2024-12-31 | 13G | Forte Biosciences, Inc. FBRX |
BIOTECHNOLOGY VALUE FUND L P | 643,622 9.990% |
643,622 (New Position) |
Filing History |
| 2025-02-14 4:07 pm Sale |
2024-12-31 | 13G | 89bio, Inc. ETNB |
BIOTECHNOLOGY VALUE FUND L P | 4,333,885 3.600% |
-2,477,746 (-36.38%) |
Filing History |
| 2025-02-14 4:05 pm Purchase |
2024-12-31 | 13G | Cidara Therapeutics, Inc. CDTX |
BIOTECHNOLOGY VALUE FUND L P | 1,093,499 9.990% |
390,373 (+55.52%) |
Filing History |
| 2025-02-14 4:02 pm Purchase |
2024-12-31 | 13G | Avalo Therapeutics, Inc. AVTX |
BIOTECHNOLOGY VALUE FUND L P | 1,038,542 9.990% |
71,243 (+7.37%) |
Filing History |
| 2025-02-04 8:09 pm Purchase |
2025-01-27 | 13G | Kura Oncology, Inc. KURA |
BIOTECHNOLOGY VALUE FUND L P | 5,912,554 7.500% |
2,504,500 (+73.49%) |
Filing History |
| 2025-02-04 8:05 pm Sale |
2024-12-31 | 13G | Kura Oncology, Inc. KURA |
BIOTECHNOLOGY VALUE FUND L P | 3,408,054 4.300% |
-804,292 (-19.09%) |
Filing History |
| 2025-01-31 6:43 pm Purchase |
2025-01-24 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
BIOTECHNOLOGY VALUE FUND L P | 4,393,210 7.200% |
4,393,210 (New Position) |
Filing History |
| 2025-01-29 5:12 pm Sale |
2025-01-27 | 13G | enGene Holdings Inc. Common Stock ENGN |
BIOTECHNOLOGY VALUE FUND L P | 945,402 1.800% |
-2,106,037 (-69.02%) |
Filing History |
| 2025-01-29 5:09 pm Sale |
2024-12-31 | 13G | enGene Holdings Inc. Common Stock ENGN |
BIOTECHNOLOGY VALUE FUND L P | 3,051,439 5.900% |
-145,000 (-4.54%) |
Filing History |
| 2025-01-28 5:19 pm Sale |
2025-01-24 | 13D | XOMA Corporation XOMA |
BIOTECHNOLOGY VALUE FUND L P | 2,983,026 25.300% |
-650,717 (-17.91%) |
Filing History |
| 2025-01-06 6:38 pm Purchase |
2024-12-27 | 13G | RAPT Therapeutics, Inc. RAPT |
BIOTECHNOLOGY VALUE FUND L P | 11,764,000 8.700% |
11,764,000 (New Position) |
Filing History |
| 2024-12-23 9:25 pm Unchanged |
2024-12-19 | 13D | Inventiva S.A. IVA |
BIOTECHNOLOGY VALUE FUND L P | 8,545,499 9.000% |
0 (Unchanged) |
Filing History |
| 2024-12-17 5:42 pm Purchase |
2024-12-13 | 13G | Palvella Therapeutics, Inc. PVLA |
BIOTECHNOLOGY VALUE FUND L P | 1,168,117 9.990% |
1,168,117 (New Position) |
Filing History |